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Abstract 
The landscape of cervical cancer prevention is changing in many countries thanks to the introduction 
of vaccination against high-risk types of human papillomavirus (HPV) and the incorporation of HPV 
DNA testing into cervical screening algorithms.  In addition to this, uptake of screening is falling year 
on year in the UK and elsewhere.  These factors present challenges and opportunities for health 
professionals working in primary care – in terms of communicating programmatic changes to 
women; responding to questions about the meaning and implications of HPV test results; and 
delivering interventions to increase screening uptake. 
Background 
In the early nineteen-sixties many believed that a population screening programme offering 
Papanicolaou (Pap) tests to all women could eliminate invasive carcinoma of the cervix (Bryder, 
2008; Boyes, Fidler, & Lock, 1962). It was another 25 years before the UK introduced its national 
cervical screening programme, which has indeed had a huge public health impact with reductions in 
cervical cancer incidence and mortality (Peto, Gilham, Fletcher, & Matthews 2004), a finding 
mirrored by many high income countries (Vaccarella, Lortet-Tieulent, Plummer, Franceschi, & Bray 
2013). There is no doubt that we have come a long way since the Papanicolaou test was first 
described with such optimism, but even countries with well-established screening programmes and 
high-level quality assurance still have the potential to further reduce cervical cancer mortality 
(Landy, Pesola, Castanon, & Sasieni 2016) and it consequently remains on the public health radar. 
The cervical screening landscape has changed dramatically over the last decade, with the 
introduction of human papillomavirus (HPV) vaccination and new opportunities for screening using 
HPV testing alongside cytology (Lorincz, Castanon, Lim, & Sasieni 2013).  These approaches have, 
and will, continue to have implications for healthcare professionals in primary care. We offer an 
overview of the current cervical cancer prevention landscape and discuss the possible implications 
that future changes will have for primary care professionals.   
Primary prevention  
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The discovery of HPV as the viral precursor that causes pre-cancerous cervical cell changes led to 
development of vaccinations that can prevent the process from ever beginning. HPV vaccination has 
been routinely offered in England since 2008 and most Western European countries now offer it for 
females in early adolescence (Bonanni et al. 2011).  The introduction of HPV vaccination has huge 
implications for the future of the cervical screening programme. Ultimately the numbers of 
precancerous cervical lesions are expected to decline (Brotherton, Gertig, May, Chappell, & Saville 
2016; Pollock et al. 2014) with far fewer women needing referral for colposcopy and treatment.    
Many early media reports suggested that HPV vaccination could mean an end to cervical screening 
(Hilton, Hunt, Langan, Bedford, & Petticrew 2010), yet this is unlikely to be the case; there are 
several reasons for this.  Firstly, the HPV vaccinations primarily used in most countries currently only 
protect against HPV types 16 and 18, which cause around 70% of cervical cancers in Europe (Munoz 
et al. 2004). This means that even vaccinated women are likely to need some screening to ensure 
cell changes caused by the remaining high-risk HPV types are picked up before becoming cancerous.  
An alternative vaccination which protects against nine HPV types has now been approved by the US 
Food and Drug Administration and the European Medicines Agency (Lopalco 2017), and estimates 
suggest this could protect against over 90% of cervical cancers (Joura et al. 2015), but there are as 
yet no plans to use this vaccination in the UK.  Secondly, even among vaccinated cohorts, there 
remain unvaccinated women who will be at higher risk of cervical cancer and for whom screening 
will be particularly important. Thirdly, women in the pre-vaccine era (i.e. born before September 
1990 in England) will continue to need screening as currently recommended, until the age of 64 
years. With the youngest of these women in their late 20s, this means cervical screening will remain 
a dominant part of the cervical cancer prevention strategy for at least another 30 years.  Healthcare 
professionals in primary care who take cervical screening samples will therefore be an important 
part of this process for the remainder of their careers.   
The first routine cohort of girls vaccinated against HPV will enter the screening programme in the UK 
in 2021, but women who were in the catch-up programme for vaccination (who were 17-18 years in 
2008) are now reaching screening age. While cervical screening will remain important for all women, 
the interplay between an individual woman’s vaccination status and her screening participation will 
contribute to her cervical cancer risk profile (Wentzensen et al. 2016). Primary care has a key role to 
play in ensuring that both vaccinated and unvaccinated women understand the potential benefits of 
screening.  Evidence from Wales, Scotland and the Netherlands (Beer et al. 2014;Palmer et al. 
2016;Herweijer et al. 2015) suggests that unvaccinated women are also less likely to attend for 
screening, creating a group of women at disproportionate risk of cervical cancer. Targeting 
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unvaccinated women with interventions designed to increase informed participation in screening 
may become an important focus of cervical cancer prevention.  
A new era for cervical screening 
Alongside the development of HPV vaccines, the last decade has seen extensive work exploring the 
potential benefits of using HPV DNA testing alongside cytology within established cervical screening 
programmes (Wentzensen et al. 2016).  Changes are now underway to move to primary HPV testing 
in several countries.  Primary HPV screening involves testing the cervical sample for high-risk HPV 
DNA initially.  Women with no high-risk HPV infection are returned to routine screening, while those 
who test positive for the virus have reflexive cytology carried out on the residual sample.  If no 
cytological abnormality is found, they are recalled for repeat HPV testing sooner than the routine 
screening interval; those with abnormal cytology are referred for colposcopy.  The Netherlands was 
the first to introduce this in 2016 (RIVM 2017) and changes are scheduled for 2017 in Australia 
(Australian Government Department of Health 2017) and 2019 in England (PHE Screening 2016).  
Using HPV testing as the primary screening tool has several benefits over cytology including 
increased test sensitivity and the potential to lengthen screening intervals for women with a 
negative HPV result (Dijkstra et al. 2016;Lorincz et al. 2013).  In general, HPV is still unfamiliar to 
many people and while written information about changes to the screening programme will be 
developed (in leaflets and online) health professionals are likely to be a key source of information; 
helping to inform women about what these changes mean.  There is therefore an urgent need to 
ensure that primary care staff are adequately trained to communicate with women about these 
changes, as previous research has shown that discussions about HPV can be seen as a ‘can of worms’ 
(McSherry et al. 2012).  One approach is the development of scripted consultations to help clinicians 
in these conversations (Hendry et al. 2016).   
Good communication about HPV testing in primary care is essential both to ensure informed choice 
when screening is being delivered, but also to ensure that if women are confused about their results, 
they can receive good information from their primary care provider.  Primary HPV testing will 
identify, for the first time, a group of women who test positive for the virus in the absence of any 
cytological abnormalities.  Little is known about how these women will make sense of their results; 
whether they will be anxious about their cancer risk, concerned with the sexually transmitted nature 
of the infection, or insufficiently concerned to attend for early recall (McBride et al. 2016).  Primary 
care staff will have a key role in ensuring that these women received clear and consistent 
information. 
Ensuring engagement 
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The introduction of HPV vaccination and the move to primary HPV testing have been at the forefront 
of discussions about cervical cancer prevention over the last ten years.  In the background however 
the same time frame has seen a steady decline in coverage of cervical screening in England, with the 
exception of a blip in this trend following the death of a UK celebrity, Jade Goody in 2009 (Lancucki, 
Sasieni, Patnick, Day, & Vessey 2012).  Coverage is lowest among the youngest women invited and 
also slightly lower than average in the oldest age groups (Screening and Immunisations Team 2016).  
Other developed countries have seen similar declines in attendance among young women (Lancucki 
et al. 2010).  Reasons for reduced engagement are unclear but it may, in part, be that screening is a 
victim of its own success with falling rates of cervical cancer meaning fewer women are aware of it 
through personal experience of relatives or friends.  If this is the case, the success of the vaccine may 
well exacerbate this further. The short-term impact of Jade Goody’s diagnosis with cervical cancer 
on screening uptake (Lancucki et al., 2012) suggests that increasing the immediate salience of the 
disease might prompt screening engagement. 
Novel ways are needed to encourage women to attend screening.  Publication of the recent 
STRATEGIC trial showed evidence that timed appointments improved attendance among non-
attenders following their first invitation for screening (Kitchener et al. 2016). It is likely that mobile 
technology can be harnessed to increase participation, through easier booking of appointments, and 
text message or email reminders (e.g. Huf 2016). In addition, the use of self-sampling for HPV testing 
is generally acceptable (Nelson et al. 2017) and shows great promise for increasing uptake in women 
who are overdue as well as those who have never attended (Sultana et al. 2016;Albrow et al. 2014). 
HPV self-sampling will become more feasible in the UK and elsewhere once HPV primary screening is 
introduced and could be particularly useful for those who are concerned about the speculum or 
cannot attend appointments.  This type of targeted intervention could be part of a broader trend to 
personalise screening information – something that primary care could be well-placed to deliver.  It 
is increasingly clear that screening non-participants are a heterogeneous group, with multiple 
different reasons for not taking part.  These range from lack of awareness of the screening 
programme through to positive intentions to take part, hampered only by competing demands on 
their time, or difficult appointment systems (Chorley, Marlow, Forster, Haddrell, & Waller 2016). A 
one-size-fits-all approach to increasing screening uptake is unlikely to be effective – indeed the only 
intervention that has consistently been shown to be effective is the use of invitations and reminders, 
something already done within organised programmes and many primary care practices (Everett et 
al. 2011).  For those women who do not respond to any population-based interventions (e.g. 
reminders, online booking, mailed self-test kits), the only opportunity to engage them in considering 
cervical screening may be opportunistically, when attending primary care for another reason.  A 
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recent study showed that around 60% of screening non-attenders in East London had attended a 
primary care appointment in the last year (Lim & Sasieni 2015), suggesting opportunistic approaches 
may be feasible.  
Conclusions 
Cervical cancer prevention is entering a period of change in many European countries, during which 
health professionals working in primary care will play a key role in delivering services and 
communicating with women.  With continued high coverage of HPV vaccination and ever improving 
screening tests, the goal of eradicating cervical cancer in many high-income countries is now closer 
than ever.  It is important to remember, though, that over 85% of cervical cancer deaths occur in low 
and middle income countries (Samarasekera & Horton 2016), so an important future priority must 
be to implement primary and secondary prevention strategies into the countries where the need is 
greatest.  Primary care professionals will likely face questions and confusion about future changes.  
Proposals to change screening, particularly when it involves taking something away (i.e. reducing the 
age-range of those eligible for screening or lengthening the screening interval), is often perceived 
negatively by the public.  In Australia for example, the proposed changes to cervical screening have 
resulted in public backlash with over 70,000 people signing a petition against the proposed changed 
(change.org, 2017).  Primary care professionals should ensure they are able to clearly articulate why 
changes are being made and the benefits they will bring (The Conversation, 2017).  This will help to 
ensure clear consistent messages are communicated in a way that maintains public confidence in 
screening.  
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